EZH2 and glioblastoma: Thus,we anticipated that the balanced concomitant modulation of EZH2 andHSP90 via the furnishing of hybrid scaffolds based on the structuralcommonalities of pharmacophores of both targets might activate thechemical architecture of tazemetostat to exert anti-GBM effects.